We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.
In cooperation with Association of Corporate Counsel
  Request new password

Search results

Order by most recent / most popular / relevance

Results: 1-10 of 599

West Virginia repeals state’s pharmaceutical advertising disclosure law

  • Cooley LLP
  • -
  • USA
  • -
  • March 30 2015

The Governor of West Virginia signed last week Senate Bill 267 to repeal the Code provisions that created the Governor's Office of Health Enhancement

One-a-day keeps the plaintiff’s lawyers away: FDA determinations on disease claims preempt class action allegations

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • March 20 2015

A California court recently dismissed, in part, a consumer class action against labeling and advertising claims for twenty different Bayer One-A-Day

Prestige Brands agrees to discontinue claims for certain Little Remedies products following NAD challenge

  • Winston & Strawn LLP
  • -
  • USA
  • -
  • March 20 2015

Pfizer Consumer Healthcare recently challenged certain claims made by Prestige Brands regarding its line of Little Remedies products for children

Court finds that class action plaintiffs’ false advertising claims are stripped Bayer based on federal preemption

  • Sheppard Mullin Richter & Hampton LLP
  • -
  • USA
  • -
  • March 17 2015

In the recent case of Gallagher v. Bayer AG, Case No. 14-cv-04601-WHO (N.D. Cal. March 10, 2015), the plaintiffs asserted that the defendants Bayer

FDA advises pharma companies to simplify consumer print ads, hopes new approach will resonate better with patients

  • Loeb & Loeb LLP
  • -
  • USA
  • -
  • March 5 2015

The FDA is recommending that drug companies aim for comprehension with their consumer-directed print ads by limiting the risk information, more fully

FTC targets mobile app makers over cancer detection claims

  • Arent Fox LLP
  • -
  • USA
  • -
  • February 27 2015

The Federal Trade Commission (FTC) announced this week that it had settled with two marketers of mobile medical apps (MMAs) New Consumer

FTC settles with health app marketers for unsubstantiated melanoma detection claims

  • Kelley Drye & Warren LLP
  • -
  • USA
  • -
  • February 25 2015

The Federal Trade Commission announced this week that it has reached settlements with two marketers for "deceptively claiming their mobile apps could

NAD recommends advertiser discontinue “1 Brand” and comparative strength claims

  • Winston & Strawn LLP
  • -
  • USA
  • -
  • February 25 2015

The National Advertising Division ("NAD") recently recommended that Splintek, Inc., a manufacturer of dental guards to protect against nighttime

First Amendment trumps FTC

  • Reed Smith LLP
  • -
  • USA
  • -
  • February 20 2015

The Federal Trade Commission has a long reach, but its grip is not quite as strong as it was before the D.C. Circuit's recent opinion in PomWonderful

Less is more in FDA’s eyes: FDA’s revised draft guidance on disclosing risk information

  • Hogan Lovells
  • -
  • USA
  • -
  • February 11 2015

On Monday, February 9, 2015, the Food and Drug Administration (FDA) published a revised draft guidance addressing disclosure of risk information